Alépée Natalie, Bahinski Anthony, Daneshian Mardas, De Wever Bart, Fritsche Ellen, Goldberg Alan, Hansmann Jan, Hartung Thomas, Haycock John, Hogberg Helena, Hoelting Lisa, Kelm Jens M, Kadereit Suzanne, McVey Emily, Landsiedel Robert, Leist Marcel, Lübberstedt Marc, Noor Fozia, Pellevoisin Christian, Petersohn Dirk, Pfannenbecker Uwe, Reisinger Kerstin, Ramirez Tzutzuy, Rothen-Rutishauser Barbara, Schäfer-Korting Monika, Zeilinger Katrin, Zurich Marie-Gabriele
L'Oréal R&I, Aulnay, France.
ALTEX. 2014;31(4):441-77. doi: 10.14573/altex.1406111. Epub 2014 Jul 14.
Integrated approaches using different in vitro methods in combination with bioinformatics can (i) increase the success rate and speed of drug development; (ii) improve the accuracy of toxicological risk assessment; and (iii) increase our understanding of disease. Three-dimensional (3D) cell culture models are important building blocks of this strategy which has emerged during the last years. The majority of these models are organotypic, i.e., they aim to reproduce major functions of an organ or organ system. This implies in many cases that more than one cell type forms the 3D structure, and often matrix elements play an important role. This review summarizes the state of the art concerning commonalities of the different models. For instance, the theory of mass transport/metabolite exchange in 3D systems and the special analytical requirements for test endpoints in organotypic cultures are discussed in detail. In the next part, 3D model systems for selected organs--liver, lung, skin, brain--are presented and characterized in dedicated chapters. Also, 3D approaches to the modeling of tumors are presented and discussed. All chapters give a historical background, illustrate the large variety of approaches, and highlight up- and downsides as well as specific requirements. Moreover, they refer to the application in disease modeling, drug discovery and safety assessment. Finally, consensus recommendations indicate a roadmap for the successful implementation of 3D models in routine screening. It is expected that the use of such models will accelerate progress by reducing error rates and wrong predictions from compound testing.
(i)提高药物研发的成功率和速度;(ii)提高毒理学风险评估的准确性;以及(iii)增进我们对疾病的理解。三维(3D)细胞培养模型是过去几年中出现的这一策略的重要组成部分。这些模型大多是器官型的,即它们旨在重现一个器官或器官系统的主要功能。这在许多情况下意味着不止一种细胞类型构成3D结构,而且基质成分通常起着重要作用。本综述总结了不同模型共性方面的最新进展。例如,详细讨论了3D系统中的物质运输/代谢物交换理论以及器官型培养中测试终点的特殊分析要求。在下一部分中,将在专门的章节中介绍并描述针对特定器官——肝脏、肺、皮肤、大脑——的3D模型系统。此外,还将介绍并讨论肿瘤建模的3D方法。所有章节都给出了历史背景,说明了方法的多样性,并强调了优缺点以及具体要求。此外,它们还涉及在疾病建模、药物发现和安全性评估中的应用。最后,共识性建议指出了在常规筛选中成功实施3D模型的路线图。预计使用此类模型将通过降低化合物测试的错误率和错误预测来加速进展。